SELB Selecta Biosciences, Inc.

19.87
+2.16  (12%)
Previous Close 17.71
Open 17.84
Price To book 0.00
Market Cap N/A
Shares 0
Volume 364,446
Short Ratio 0.00
Av. Daily Volume 83,580

SEC filingsSee all SEC filings

  1. 8-K - Current report 17923167
  2. 8-K - Current report 17920880
  3. 8-K - Current report 17912427
  4. 8-K - Current report 17903808
  5. CT ORDER - Confidential treatment order 17896157

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 dosing commenced late October 2016. Initial data released at EULAR June 15, 2017.
SEL-212
Tophaceous gout

Latest News

  1. Selecta Biosciences Announces $50 Million Private Placement
  2. Selecta Biosciences Announces Addition of Patrick J. Zenner to Board of Directors
  3. Selecta Biosciences (SELB) In Focus: Stock Moves 6.5% Higher
  4. Selecta Biosciences Reports Data from Ongoing Phase 2 Trial of Lead Candidate, SEL-212, in Development for Chronic Severe Gout
  5. ETFs with exposure to Selecta Biosciences, Inc. : June 6, 2017
  6. Selecta Biosciences Announces Upcoming Clinical Presentations
  7. Selecta Biosciences, Inc. :SELB-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017
  8. Selecta Biosciences to Present at the Jefferies Global Healthcare Conference on June 7, 2017
  9. Selecta Biosciences Announces New Preclinical Gene Therapy Data at the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
  10. Edited Transcript of SELB earnings conference call or presentation 11-May-17 9:00pm GMT
  11. Selecta Biosciences Announces First Quarter 2017 Financial Results and Provides Corporate Update
  12. Selecta Biosciences Commences Dosing in Phase 1 Clinical Trial of Nicotine Vaccine for Smoking Cessation and Relapse Prevention
  13. Selecta Biosciences to Report First Quarter 2017 Financial Results on Thursday, May 11, 2017
  14. Ready for Launch: Selecta Biosciences Inc. Jumps as Much as 16%
  15. Selecta Biosciences Obtains License for Recombinant Immunotoxin LMB-100 from National Cancer Institute (NCI) for Pancreatic Cancer, Mesothelioma and Other Cancers
  16. Selecta Biosciences Announces Presentations at the 20th Annual Meeting of the American Society of Gene & Cell Therapy
  17. ETFs with exposure to Selecta Biosciences, Inc. : April 26, 2017
  18. Selecta Biosciences to Present at Two Upcoming Investor Conferences in May
  19. Selecta Biosciences, Inc. :SELB-US: Earnings Analysis: Q4, 2016 By the Numbers : March 30, 2017

SEC Filings

  1. 8-K - Current report 17923167
  2. 8-K - Current report 17920880
  3. 8-K - Current report 17912427
  4. 8-K - Current report 17903808
  5. CT ORDER - Confidential treatment order 17896157
  6. 10-Q - Quarterly report [Sections 13 or 15(d)] 17834847
  7. 8-K - Current report 17834400
  8. CT ORDER - Confidential treatment order 17817179
  9. 8-K - Current report 17802969
  10. DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material 17781187